TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders
Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m
